U.S. Supreme Court to weigh key standard in whistleblower fraud cases

By Brendan Pierson (Reuters) – The U.S. Supreme Court on Friday agreed to consider reviving two lawsuits accusing pharmacy operators of overbilling government health insurance programs for prescription drugs, a dispute that could have broad implications for whistleblowers and the government’s ability to go after fraud. The key question in both cases is whether companies can shield themselves from whistleblower fraud lawsuits by pointing to an “objectively reasonable” interpretation of the law that supports their conduct – regardless of whether they actually believed that interpretation in good…

Read More